Subscribe
FDA approved risankizumab for children aged 6 years or older with moderate to severe plaque psoriasis or active psoriatic arthritis.
Tirzepatide Plus Ixekizumab Improves Outcomes in Psoriatic Arthritis With Obesity: AAD 2026
US FDA Approves First and Only TYK2 Inhibitor for the Treatment of Psoriatic Arthritis
FDA Approves Guselkumab for Pediatric Plaque Psoriasis, Active Psoriatic Arthritis: Daily Dose
FDA Approves Guselkumab for Pediatric Plaque Psoriasis and Active Psoriatic Arthritis
Kamel Abou Hussein, MD; Sushil Bhardwaj, MD, FACP
Neil M. Iyengar, MD; Swati Vishwanathan, MD
1 Session is Available!
3 Sessions are Available!
Sarah M. Tolaney, MD, MPH; Yelda Nouri, MD
Daniela A. Bota, MD, PhD; Maya Hrachova, DO
Geoffrey Ku, MD; Girish Kunapareddy, MD
2 Sessions are Available!
Jonathan Barratt, PhD, FRCP; Brendon L. Neuen, MBBS, PhD, MSc
Tiffany A. Traina, MD, FASCO; Nour Abuhadra, MD; Joshua Z. Drago, MD, MS; Ruth O’Regan, MD; Vered Stearns, MD, FASCO; Neil Vasan, MD, PhD; Anna Weiss, MD
Shubham Pant, MD, MBBS; Alison Schram, MD; Helena Yu, MD
Ilan Melnick, MD; Linda Collado, MD, DABPN, FAPA; Maria Collado, MD, FAPA
Dilsher S. Dhoot, MD, FASRS
Deep Parikh, MD
Matthew Heeney, MD; Biree Andemariam, MD
Mile Brujic, OD, FAAO; Pierce Kenworthy, OD, FAAO; Blair Lonsberry, MS, OD, MEd, FAAO
James F. Howard Jr, MD, FAAN; Tuan Vu, MD